It’s time for another edition of Reading Roundup featuring the top blog posts of May 2017. Start off your week by catching up on what the pharmaceutical industry was reading in May.
This year’s Facility of the Year Award (FOYA) Banquet honored the projects of eight different innovative companies from the US, Ireland, Puerto Rico, and Indonesia.
Find out how industry leaders responded when they were asked what 2017 has in store for the pharmaceutical industry and who they believe are its most important players. This article can also be found in the 2017 January/February edition of Pharmaceutical Engineering® magazine.
Learn about the rising importance of data integrity, what critical issues were discussed at the Data Integrity Workshop, and how to avoid the twenty-five words that no manufacturer wants to hear.
To the pharmaceutical industry, quality is a commitment to those that rely on a company’s products. Find out more about the importance of customer-focused quality, and how non-traditional technology, data, and monitoring processes improve it.
With the edition of EU Regulation No. 536/2014 Annex V, there are new regulations in place for clinical labeling requirements. Learn more about the updated rules between labeling different kinds of medicinal products.
The following blog post was provided by Peyton Myers, an undergraduate student at Appalachian State University. Myers attended the 2023 ISPE Annual Meeting & Expo in Las Vegas as an ISPE Foundation Professional Development Grant recipient.
The integration of data science in biopharmaceutical manufacturing, emphasizing data quality, tech transfer efficiency, and process optimization, is the heart of this track. Led by industry experts, discussions explore leveraging digital twins, predictive analytics, and continuous improvement initiatives. Additionally, interactive roundtable discussions provide attendees with a dynamic forum...
The pharmaceutical sector stands at a crossroads of immense possibilities. We are witnessing an unprecedented surge in innovation, fueled by a remarkable partnership between industry and regulatory authorities. For example, there are initiatives fostered by the US Food and Drug Administration (US FDA) to promote innovation with programs such as CATT (CBER Advanced Technologies Team) and ETP...
